Trial Profile
Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia; Left ventricular dysfunction
- Focus Therapeutic Use
- Acronyms IRONMAN
- 29 Aug 2023 According to a Pharmacosmos media release, based on results from this trial the Monofer (ferric derisomaltose) is now recommended in the ESC heart failure guidelines for reducing the risk of hospitalisations for heart failure (Class IIa recommendation) in symptomatic patients with iron deficiency and heart failure (HFrEF & HFmrEF).
- 07 Nov 2022 Trial design presented at the American Heart Association Scientific Sessions 2022
- 01 Nov 2022 According to a Pharmacosmos media release, the trial had a median follow-up of 2.7 years and was published in the Lancet in November 2022.